Menu
Enrolling by invitation NCT06942819

MRI Outcomes of VersaWrap Nerve Protector Following Surgery

Observational Lumbar Decompression

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: VersaWrap Nerve Protector.
Who it may be relevant to
Registry conditions: Lumbar Decompression. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Magnetic Resonance Imaging (MRI) Outcomes of VersaWrap Verve Protector Following Lumbar Decompression Surgery

Overview

The purpose of this study is to evaluate enhancement patterns in magnetic resonance imaging (MRI) evidence following the use of VersaWrap in bilateral lumbar decompression surgeries.

Detailed description

This study is a prospective, post-market, observational multi-center evaluation of the use of VersaWrap. Patients identified by the Investigator in their practice as needing a bilateral lumbar decompression at one level (L4-S1) and meeting all the inclusion and none of the exclusion criteria. Patients will consent to participating in the study, prior to any study procedures.

Interventions

  • Device VersaWrap Nerve Protector
    VersaWrap Nerve Protector is applied to the nerve root to protect the surrounding tissues

Primary outcome measures

  • MRI [Time frame: 4 months]

Eligibility criteria

Inclusion criteria

  • Patients aged ≥18 and ≤65 at time of surgery
  • Patients undergoing lumbar decompression bilaterally at one level from L4-S1
  • Psychologically, mentally and physically able to fully comply with this protocol including adhering to follow-up schedule, study requirements with a signed informed consent.

Exclusion criteria

  • Non-English speaking
  • Known allergy or sensitivity to citrate, alginate or hyaluronate
  • Known allergy or sensitivity to MRI contrast dye
  • Known to experience claustrophobia
  • Pregnant or breastfeeding at time of surgery
  • Incarcerated at time of surgery
  • Prior lumbar surgery at the index level
  • Conjunction device use at index level (i.e., Barricade)\*
  • Patient has any condition, that in the opinion of the Investigator, would prohibit the patient from complying with the protocol \*Note: conjunction medications (i.e., Depo-Medrol, Marcaine/Epinephrine) are acceptable

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • Austin Neurosurgeons — Austin

Identifiers

NCT: NCT06942819 · TP-081

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗